TW201509943A - 含有小於２５ｐｐｍ１４-羥可待因酮之羥可酮鹽酸鹽之組成物、醫藥劑型、延遲釋出口服劑型及醫藥上可以接受的包裝 - Google Patents

含有小於２５ｐｐｍ１４-羥可待因酮之羥可酮鹽酸鹽之組成物、醫藥劑型、延遲釋出口服劑型及醫藥上可以接受的包裝 Download PDF

Info

Publication number
TW201509943A
TW201509943A TW103140205A TW103140205A TW201509943A TW 201509943 A TW201509943 A TW 201509943A TW 103140205 A TW103140205 A TW 103140205A TW 103140205 A TW103140205 A TW 103140205A TW 201509943 A TW201509943 A TW 201509943A
Authority
TW
Taiwan
Prior art keywords
hydroxycodeinone
ppm
oxycodone
less
oxycodone hydrochloride
Prior art date
Application number
TW103140205A
Other languages
English (en)
Chinese (zh)
Inventor
Robert Chapman
Lonn S Rider
Qi Hong
Donald Kyle
Robert Kupper
Original Assignee
Euro Celtique Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35124996&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TW201509943(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Euro Celtique Sa filed Critical Euro Celtique Sa
Publication of TW201509943A publication Critical patent/TW201509943A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/06—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with a hetero atom directly attached in position 14
    • C07D489/08—Oxygen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4833—Encapsulating processes; Filling of capsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/02—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with oxygen atoms attached in positions 3 and 6, e.g. morphine, morphinone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/02—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with oxygen atoms attached in positions 3 and 6, e.g. morphine, morphinone
    • C07D489/04—Salts; Organic complexes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicinal Preparation (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW103140205A 2004-03-30 2005-03-15 含有小於２５ｐｐｍ１４-羥可待因酮之羥可酮鹽酸鹽之組成物、醫藥劑型、延遲釋出口服劑型及醫藥上可以接受的包裝 TW201509943A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US55749204P 2004-03-30 2004-03-30
US60153404P 2004-08-13 2004-08-13
US62007204P 2004-10-18 2004-10-18
US64862505P 2005-01-31 2005-01-31
US65177805P 2005-02-10 2005-02-10

Publications (1)

Publication Number Publication Date
TW201509943A true TW201509943A (zh) 2015-03-16

Family

ID=35124996

Family Applications (3)

Application Number Title Priority Date Filing Date
TW103140205A TW201509943A (zh) 2004-03-30 2005-03-15 含有小於２５ｐｐｍ１４-羥可待因酮之羥可酮鹽酸鹽之組成物、醫藥劑型、延遲釋出口服劑型及醫藥上可以接受的包裝
TW094107824A TWI365880B (en) 2004-03-30 2005-03-15 Process for preparing oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone and oxycodone hydrochloride composition,pharmaceutical dosage form,sustained release oeal dosage form and pharmaceutically acceptable package having less than 25 pp
TW101106699A TWI483944B (zh) 2004-03-30 2005-03-15 含有小於２５ｐｐｍ１４-羥可待因酮之羥可酮鹽酸鹽組成物、醫藥劑型、延遲釋出口服劑型及醫藥上可以接受的包裝

Family Applications After (2)

Application Number Title Priority Date Filing Date
TW094107824A TWI365880B (en) 2004-03-30 2005-03-15 Process for preparing oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone and oxycodone hydrochloride composition,pharmaceutical dosage form,sustained release oeal dosage form and pharmaceutically acceptable package having less than 25 pp
TW101106699A TWI483944B (zh) 2004-03-30 2005-03-15 含有小於２５ｐｐｍ１４-羥可待因酮之羥可酮鹽酸鹽組成物、醫藥劑型、延遲釋出口服劑型及醫藥上可以接受的包裝

Country Status (38)

Country Link
US (35) US7129248B2 (https=)
EP (7) EP2316837B1 (https=)
JP (8) JP4912294B2 (https=)
KR (12) KR100930730B1 (https=)
CN (5) CN1960994B (https=)
AP (1) AP2232A (https=)
AR (1) AR049012A1 (https=)
AT (2) ATE501150T1 (https=)
AU (2) AU2005230826C1 (https=)
BR (1) BRPI0508758B8 (https=)
CA (3) CA2774121C (https=)
CR (2) CR8593A (https=)
CY (5) CY1111487T1 (https=)
DE (2) DE602005026786D1 (https=)
DK (6) DK1730151T4 (https=)
EA (1) EA013208B1 (https=)
EC (1) ECSP066953A (https=)
ES (6) ES2362282T5 (https=)
FI (1) FI7843U1 (https=)
HR (5) HRP20110425T4 (https=)
HU (3) HUE036451T2 (https=)
IL (8) IL178038A (https=)
LT (2) LT2316837T (https=)
MA (1) MA28492B1 (https=)
ME (4) ME02411B (https=)
MX (2) MX363228B (https=)
MY (3) MY172063A (https=)
NO (1) NO337669B1 (https=)
NZ (3) NZ549430A (https=)
PE (1) PE20050880A1 (https=)
PL (5) PL2319846T3 (https=)
PT (5) PT2305683E (https=)
RS (5) RS51693B2 (https=)
SG (3) SG170736A1 (https=)
SI (5) SI1730151T2 (https=)
TW (3) TW201509943A (https=)
WO (1) WO2005097801A1 (https=)
ZA (1) ZA200607181B (https=)

Families Citing this family (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
DE102004020220A1 (de) * 2004-04-22 2005-11-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform
EP1658054B1 (de) * 2003-08-06 2007-06-27 Grünenthal GmbH Gegen missbrauch gesicherte darreichungsform
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE10336400A1 (de) * 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
US20070048228A1 (en) * 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
US8075872B2 (en) 2003-08-06 2011-12-13 Gruenenthal Gmbh Abuse-proofed dosage form
DE102005005446A1 (de) * 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
US7201920B2 (en) 2003-11-26 2007-04-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of opioid containing dosage forms
TW201509943A (zh) 2004-03-30 2015-03-16 Euro Celtique Sa 含有小於２５ｐｐｍ１４-羥可待因酮之羥可酮鹽酸鹽之組成物、醫藥劑型、延遲釋出口服劑型及醫藥上可以接受的包裝
DE102004032103A1 (de) * 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
DE102004032049A1 (de) * 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
GB0421149D0 (en) * 2004-09-23 2004-10-27 Johnson Matthey Plc Preparation of oxycodone
US20080152595A1 (en) * 2004-11-24 2008-06-26 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of orally administered pharmaceutical products
DE102005005449A1 (de) * 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
ME01594B (me) * 2005-03-04 2014-09-20 Euro Celtique Sa Postupak smanjenja alfa, beta nezasićenih ketona u opioidnim kompozicijama
US20070082845A1 (en) * 2005-07-15 2007-04-12 The Penn State Research Foundation Ferritin as a therapeutic target in abnormal cells
CA2630703C (en) * 2005-11-22 2014-05-20 Controlled Chemicals, Inc. Processes for reducing contaminating michael acceptor levels in oxycodone and other compositions
US20070117826A1 (en) * 2005-11-23 2007-05-24 Forest Laboratories, Inc. Pharmaceutical formulations comprising ibuprofen, oxycodone, and 14-hydroxycodeinone
CN101395159A (zh) * 2006-03-02 2009-03-25 马林克罗特公司 制备含有低含量α,β-不饱和酮化合物的吗啡烷-6-酮产物的方法
SA07280459B1 (ar) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
CA2674915C (en) 2006-10-17 2015-06-30 Penick Corporation Process for preparing oxymorphone
AU2007313103C1 (en) * 2006-10-17 2014-01-30 Penick Corporation Process for preparing oxymorphone
US20080125592A1 (en) * 2006-10-17 2008-05-29 Penick Corporation Process for preparing oxymorphone, naltrexone, and buprenorphine
ES2393221T3 (es) * 2006-12-04 2012-12-19 Noramco, Inc. Procedimiento de preparación de oxicodona con niveles reducidos de 14-hidroxicodeinona
WO2008070656A2 (en) * 2006-12-04 2008-06-12 Noramco, Inc Process for reducing impurities in oxycodone base
GB0624880D0 (en) * 2006-12-14 2007-01-24 Johnson Matthey Plc Improved method for making analgesics
DE102007011485A1 (de) 2007-03-07 2008-09-11 Grünenthal GmbH Darreichungsform mit erschwertem Missbrauch
ES2438997T5 (es) * 2007-03-23 2024-09-03 SpecGx LLC Preparación mejorada de oximorfona a partir de oripavina
CA2684458A1 (en) * 2007-04-16 2008-10-30 Mallinckrodt Inc. Novel opiate reduction utilizing catalytic hydrogen transfer reaction
CA2713128C (en) 2008-01-25 2016-04-05 Gruenenthal Gmbh Pharmaceutical dosage form
WO2009114648A1 (en) * 2008-03-11 2009-09-17 Depomed Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
US8372432B2 (en) * 2008-03-11 2013-02-12 Depomed, Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
AU2009243681B2 (en) 2008-05-09 2013-12-19 Grunenthal Gmbh Process for the preparation of an intermediate powder formulation and a final solid dosage form under usage of a spray congealing step
BRPI0913724B8 (pt) * 2008-09-18 2021-05-25 Purdue Pharma Lp formas farmacêuticas de liberação prolongada compreendendo naltrexona e poli (e-caprolactona) e seu preparo
KR101738369B1 (ko) * 2009-07-22 2017-05-22 그뤼넨탈 게엠베하 핫 멜트 압출된 제어 방출 투여형
CN102639118B (zh) 2009-07-22 2015-07-29 格吕伦塔尔有限公司 氧化稳定的抗干扰剂型
PL399450A1 (pl) * 2009-08-31 2013-01-21 Depomed, Inc Utrzymujace sie w zoladku kompozycje farmaceutyczne do natychmiastowego i przedluzonego uwalniania acetaminofenu
AU2010300641B2 (en) 2009-09-30 2016-03-17 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse
US8597681B2 (en) 2009-12-22 2013-12-03 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
US9198861B2 (en) 2009-12-22 2015-12-01 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
ES2606227T3 (es) * 2010-02-03 2017-03-23 Grünenthal GmbH Preparación de una composición farmacéutica en polvo mediante una extrusora
EP2377866B1 (en) 2010-03-23 2014-02-26 Siegfried AG Preparation of low impurity opiates in a continuous flow reactor
EP2568965A1 (en) 2010-05-10 2013-03-20 Euro-Celtique S.A. Combination of active loaded granules with additional actives
US9700508B2 (en) 2010-05-10 2017-07-11 Euro-Celtique S.A. Pharmaceutical compositions comprising hydromorphone and naloxone
PH12012502083A1 (en) 2010-05-10 2017-07-26 Euro Celtique Sa Manufacturing of active-free granules and tablets comprising the same
CA2802294C (en) 2010-06-11 2016-05-10 Rhodes Technologies Process for n-dealkylation of tertiary amines
EP2580201B1 (en) 2010-06-11 2017-08-02 Rhodes Technologies Transition metal-catalyzed processes for the preparation of n-allyl compounds and use thereof
PL2588481T3 (pl) 2010-07-02 2018-05-30 Johnson Matthey Public Limited Company Sposób syntezy i oczyszczania oksykodonu
US8912781B2 (en) * 2010-07-30 2014-12-16 Cirrus Logic, Inc. Integrated circuit switching power supply controller with selectable buck mode operation
BR112013005194A2 (pt) 2010-09-02 2016-05-03 Gruenenthal Gmbh forma de dosagem resistente à violação compreendendo sal inorgânico
TWI516286B (zh) 2010-09-02 2016-01-11 歌林達股份有限公司 含陰離子聚合物之抗破碎劑型
US8741885B1 (en) 2011-05-17 2014-06-03 Mallinckrodt Llc Gastric retentive extended release pharmaceutical compositions
US8858963B1 (en) 2011-05-17 2014-10-14 Mallinckrodt Llc Tamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia
US9050335B1 (en) 2011-05-17 2015-06-09 Mallinckrodt Llc Pharmaceutical compositions for extended release of oxycodone and acetaminophen resulting in a quick onset and prolonged period of analgesia
BR112014001091A2 (pt) 2011-07-29 2017-02-14 Gruenenthal Gmbh comprimido resistente à adulteração que fornece liberação imediata do fármaco
EA201400172A1 (ru) 2011-07-29 2014-06-30 Грюненталь Гмбх Устойчивая к разрушению таблетка, которая обеспечивает немедленное высвобождение лекарственного средства
EP2748000B1 (en) 2011-09-05 2020-11-18 Siegfried Ltd. Kit comprising a packaging material and a solid pharmaceutical or nutraceutical product contained in the packaging material
ES2583132T3 (es) 2011-09-16 2016-09-19 Purdue Pharma L.P. Formulaciones de liberación inmediata resistentes a alteración
JP6110384B2 (ja) 2011-09-16 2017-04-05 パーデュー ファーマ エルピー 不正改変抵抗性医薬製剤
CN104010630A (zh) 2011-12-09 2014-08-27 普渡制药公司 包含聚(ε-己内酯)和聚氧乙烯的药物剂型
MX356421B (es) 2012-02-28 2018-05-29 Gruenenthal Gmbh Forma de dosificacion resistente a la manipulacion indebida que comprende un compuesto farmacologicamente activo y un polimero anionico.
CN109820830A (zh) 2012-03-02 2019-05-31 罗德兹制药股份有限公司 抗破坏性立即释放型制剂类
KR102082529B1 (ko) 2012-04-17 2020-02-27 퍼듀 퍼머 엘피 오피오이드-유도 유해 약역학 반응을 치료하기 위한 시스템 및 방법
EP2838512B1 (en) 2012-04-18 2018-08-22 Grünenthal GmbH Tamper resistant and dose-dumping resistant pharmaceutical dosage form
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
EP2872121B1 (en) 2012-07-12 2018-09-05 SpecGx LLC Extended release, abuse deterrent pharmaceutical compositions
KR101946104B1 (ko) 2012-07-16 2019-02-08 로드스 테크놀로지즈 개선된 오피오이드 합성을 위한 방법
EP2872516B1 (en) * 2012-07-16 2017-08-30 Rhodes Technologies Process for improved opioid synthesis
PL2880037T3 (pl) * 2012-08-03 2019-07-31 Johnson Matthey Public Limited Company Sposób wytwarzania oksykodonu
MX366159B (es) 2012-11-30 2019-07-01 Acura Pharmaceuticals Inc Liberacion autorregulada de ingrediente farmaceutico activo.
MX2015010041A (es) 2013-02-05 2015-10-30 Purdue Pharma Lp Formulacion farmaceuticas resistentes a la alteracion.
US9770710B2 (en) 2013-02-20 2017-09-26 University Of Washington Through Its Center For Commercialization Hydrogenation and disproportionation catalysis
US10751287B2 (en) 2013-03-15 2020-08-25 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
US9737490B2 (en) 2013-05-29 2017-08-22 Grünenthal GmbH Tamper resistant dosage form with bimodal release profile
EP3003279A1 (en) 2013-05-29 2016-04-13 Grünenthal GmbH Tamper-resistant dosage form containing one or more particles
BR112016000194A8 (pt) 2013-07-12 2019-12-31 Gruenenthal Gmbh forma de dosagem resistente à violação contendo o polímero de acetato de etileno-vinila
GB201313211D0 (en) 2013-07-24 2013-09-04 Cambrex Karlskoga Ab New process
GB201313915D0 (en) * 2013-08-02 2013-09-18 Johnson Matthey Plc Process
CA2919602C (en) 2013-08-02 2018-03-13 Johnson Matthey Public Limited Company Process for the preparation of oxymorphone
BR112016008459B1 (pt) 2013-11-07 2023-02-07 SpecGx LLC Produção de morfinanos de 6-hidroxi sem isolamento de intermediários
WO2015071380A1 (en) 2013-11-13 2015-05-21 Euro-Celtique S.A. Hydromorphone and naloxone for treatment of pain and opioid bowel dysfunction syndrome
EP3073994A1 (en) 2013-11-26 2016-10-05 Grünenthal GmbH Preparation of a powdery pharmaceutical composition by means of cryo-milling
US9062062B1 (en) 2013-12-18 2015-06-23 Cody Laboratories, Inc. Synthesis of oxycodone hydrochloride
US10227354B2 (en) 2013-12-18 2019-03-12 Cody Laboratories, Inc. Conversion of oxycodone base to oxycodone hydrochloride
US8846923B1 (en) 2013-12-18 2014-09-30 Cody Laboratories, Inc. Preparation of 14-hydroxycodeinone sulfate
KR101868723B1 (ko) 2014-01-15 2018-06-18 로드스 테크놀로지즈 개선된 옥시코돈 합성을 위한 방법
EP3094633B1 (en) 2014-01-15 2018-03-14 Rhodes Technologies Process for improved oxymorphone synthesis
WO2015120201A1 (en) 2014-02-05 2015-08-13 Kashiv Pharma, Llc Abuse-resistant drug formulations with built-in overdose protection
WO2015145461A1 (en) 2014-03-26 2015-10-01 Sun Pharma Advanced Research Company Ltd. Abuse deterrent immediate release biphasic matrix solid dosage form
WO2015173195A1 (en) 2014-05-12 2015-11-19 Grünenthal GmbH Tamper resistant immediate release capsule formulation comprising tapentadol
EA201692388A1 (ru) 2014-05-26 2017-05-31 Грюненталь Гмбх Лекарственная форма в виде множества частиц, защищенная от вызываемого этанолом сброса дозы
MA40332A (fr) 2014-07-09 2021-04-28 Rhodes Tech Réduction des niveaux de cétone alpha, beta-insaturée dans des compositions de dérivés de morphinane
CA2910865C (en) 2014-07-15 2016-11-29 Isa Odidi Compositions and methods for reducing overdose
US20160052932A1 (en) 2014-08-25 2016-02-25 Johnson Matthey Public Limited Company Processes for Making Opioids Including 14-Hydroxycodeinone and 14-hydroxymorphinone
US9849124B2 (en) 2014-10-17 2017-12-26 Purdue Pharma L.P. Systems and methods for treating an opioid-induced adverse pharmacodynamic response
CN105777766B (zh) * 2014-12-15 2017-11-24 北大方正集团有限公司 Delta‑7溴甲纳曲酮的制备方法
US9918979B2 (en) * 2015-01-29 2018-03-20 Johnson Matthey Public Limited Company Process of preparing low ABUK oxymorphone hydrochloride
WO2016170097A1 (en) 2015-04-24 2016-10-27 Grünenthal GmbH Tamper-resistant dosage form with immediate release and resistance against solvent extraction
GB201513203D0 (en) 2015-07-27 2015-09-09 Cambrex Charles City Inc New process
US11103581B2 (en) 2015-08-31 2021-08-31 Acura Pharmaceuticals, Inc. Methods and compositions for self-regulated release of active pharmaceutical ingredient
JP2018526414A (ja) 2015-09-10 2018-09-13 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 乱用抑止性の即放性製剤を用いた経口過剰摂取に対する保護
US9943513B1 (en) 2015-10-07 2018-04-17 Banner Life Sciences Llc Opioid abuse deterrent dosage forms
US10335405B1 (en) 2016-05-04 2019-07-02 Patheon Softgels, Inc. Non-burst releasing pharmaceutical composition
WO2018055199A1 (en) 2016-09-26 2018-03-29 Euro-Celtique S.A. Methods of treatment comprising administering a high daily dose of oxycodone and naloxone in a 2:1 weight ratio
US10335375B2 (en) 2017-05-30 2019-07-02 Patheon Softgels, Inc. Anti-overingestion abuse deterrent compositions
EP3642207B1 (en) * 2017-06-20 2022-08-31 Johnson Matthey Public Limited Company Hydrogenation process for preparing oxycodone hydrochloride from 14-hydroxycodeinone
JP2020526500A (ja) 2017-06-30 2020-08-31 パーデュー、ファーマ、リミテッド、パートナーシップ 治療方法及びその剤形
CN110330500B (zh) * 2019-07-12 2021-11-23 宜昌人福药业有限责任公司 一种6β-羟基-7,8-二氢-吗啡衍生物的立体选择性合成方法
CN113009060B (zh) * 2021-02-24 2022-10-21 西南药业股份有限公司 高效液相色谱法测定盐酸羟考酮含量的方法

Family Cites Families (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1468805A (en) 1923-09-25 Htabtin ereund
US1485673A (en) 1924-03-04 Ministrator
DE296916C (https=) *
US100000A (en) * 1870-02-22 Improved sun-bonnet for horses
US105553A (en) 1870-07-19 Improvement in kettle for melting, mixing, and casting metals
DE286431C (https=)
US420098A (en) * 1890-01-28 Mowing-machine
US710223A (en) * 1901-06-10 1902-09-30 Thew Automatic Shovel Company Power-shovel.
SU64699A1 (ru) 1944-01-26 1944-11-30 А.И. Лютенберг Способ получени сол нокислого дигидрооксикодеинона
ES212554A1 (es) 1953-12-01 1954-08-16 Casanovas Albajes Cesar Un procedimiento para la obtención de un vidrio orgánico
US2772270A (en) 1954-10-21 1956-11-27 M J Lewenstein 14-hydroxymorphinone and 8, 14-dihydroxydihydromorphinone
US2806033A (en) 1955-08-03 1957-09-10 Lewenstein Morphine derivative
US3173878A (en) * 1960-02-26 1965-03-16 Ibm Process of making microcapsules
US3173876A (en) 1960-05-27 1965-03-16 John C Zobrist Cleaning methods and compositions
NL271831A (https=) 1960-11-29
US3276586A (en) 1963-08-30 1966-10-04 Rosaen Filter Co Indicating means for fluid filters
US3916898A (en) 1964-05-20 1975-11-04 Searle & Co Administration of medicaments and the like
NL6714885A (https=) 1967-11-02 1969-05-06
US3541006A (en) 1968-07-03 1970-11-17 Amicon Corp Ultrafiltration process
US3541005A (en) 1969-02-05 1970-11-17 Amicon Corp Continuous ultrafiltration of macromolecular solutions
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US3905981A (en) 1973-10-12 1975-09-16 Research Corp N-dealkylation of tertiary amines
US3894026A (en) 1973-10-16 1975-07-08 Merck & Co Inc Production of thebaine
GB1478759A (en) 1974-11-18 1977-07-06 Alza Corp Process for forming outlet passageways in pills using a laser
US4077407A (en) 1975-11-24 1978-03-07 Alza Corporation Osmotic devices having composite walls
US4063064A (en) 1976-02-23 1977-12-13 Coherent Radiation Apparatus for tracking moving workpiece by a laser beam
US3984026A (en) * 1976-03-26 1976-10-05 Shoup Russel W Combined can opening and sealing device
US4045440A (en) 1976-09-16 1977-08-30 The United States Of America As Represented By The Department Of Health, Education And Welfare Method of producing thebaine from codeine and oripavine from morphine
US4285987A (en) 1978-10-23 1981-08-25 Alza Corporation Process for manufacturing device with dispersion zone
US4200098A (en) 1978-10-23 1980-04-29 Alza Corporation Osmotic system with distribution zone for dispensing beneficial agent
US4272540A (en) 1979-04-24 1981-06-09 Sisa, Incorporated 14-Methoxymorphinan-6-one compounds and therapeutic methods of treating pain and drug dependence with them
US4370333A (en) 1981-06-29 1983-01-25 Sisa, Incorporated 17-Cyclopropylmethyl-3-hydroxy-14-methoxy 7α-methyl-morphinan-6-one and therapeutic method of treating pain with it
US4795813A (en) 1981-08-17 1989-01-03 The Florida Board Of Regents On Behalf Of The Florida State University Synthesis of derivatives of codeine and other 3-O-alkylmorphines
US5112975A (en) 1984-03-27 1992-05-12 Mallinckrodt Specialty Chemicals Company Preparation of noroxymorphone from morphine
US4639520A (en) 1984-03-27 1987-01-27 Mallinckrodt, Inc. Preparation of 14-hydroxy-N-ethoxy-carbonyl-norcodeinone
US4861598A (en) 1986-07-18 1989-08-29 Euroceltique, S.A. Controlled release bases for pharmaceuticals
US4810699A (en) 1987-02-20 1989-03-07 American Home Products Corporation Substituted 1,3,4,9-tetrahydropyrano[3,4,-b]indole-1-acetic acids, pharmaceutical compositions containing them, and methods for treating inflammatory conditions and for analgesic purposes using them
US4810669A (en) * 1987-07-07 1989-03-07 Oki Electric Industry Co., Ltd. Method of fabricating a semiconductor device
DE3812567A1 (de) 1988-04-15 1989-10-26 Basf Ag Verfahren zur herstellung pharmazeutischer mischungen
HU208633B (en) 1991-02-04 1993-12-28 Alkaloida Vegyeszeti Gyar Process for production of analgetic compositions as applicable for blocking of opioid-binding spaces /2-receptors/ causing respiration depression
US5215758A (en) 1991-09-11 1993-06-01 Euroceltique, S.A. Controlled release matrix suppository for pharmaceuticals
US5266331A (en) 1991-11-27 1993-11-30 Euroceltique, S.A. Controlled release oxycodone compositions
US5656295A (en) 1991-11-27 1997-08-12 Euro-Celtique, S.A. Controlled release oxycodone compositions
US5273760A (en) 1991-12-24 1993-12-28 Euroceltigue, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US5286493A (en) 1992-01-27 1994-02-15 Euroceltique, S.A. Stabilized controlled release formulations having acrylic polymer coating
US5472712A (en) 1991-12-24 1995-12-05 Euroceltique, S.A. Controlled-release formulations coated with aqueous dispersions of ethylcellulose
US5324351A (en) 1992-08-13 1994-06-28 Euroceltique Aqueous dispersions of zein and preparation thereof
JP3433871B2 (ja) * 1996-01-26 2003-08-04 株式会社デンソー 集積化半導体歪みセンサ及びその製造方法
EP1014941B2 (en) 1996-06-26 2017-05-17 The Board Of Regents, The University Of Texas System Hot-melt extrudable pharmaceutical formulation
US5869669A (en) 1996-07-26 1999-02-09 Penick Corporation Preparation of 14-hydroxynormorphinones from normorphinone dienol acylates
ES2121554B1 (es) * 1996-12-23 1999-06-16 Univ Santiago Compostela Procedimiento de obtencion de 14-hidroximofinonas mediante fotooxidac ion de alcaloides morfinicos con sistema alcoxidienico en el anillo c.
GB9713703D0 (en) 1997-06-30 1997-09-03 Johnson Matthey Plc Preparation of opiates
GB9717629D0 (en) 1997-08-21 1997-10-22 Johnson Matthey Plc Removal of residual organic solvents
US6710223B1 (en) 1997-09-10 2004-03-23 The Procter & Gamble Company Method for improving skin condition
GB9805516D0 (en) 1998-03-17 1998-05-13 Johnson Matthey Plc Preparation of opiates
EP1358987A3 (en) * 1998-10-14 2004-03-03 Gyros AB A replication matrix
US6177567B1 (en) 1999-10-15 2001-01-23 Boehringer Ingelheim Chemicals, Inc. Method for preparing oxycodone
US6284769B1 (en) * 1999-12-03 2001-09-04 The Board Of Trustees Of The University Of Illinois Nonpeptide kappa opioid receptor antagonists
US6133132A (en) * 2000-01-20 2000-10-17 Advanced Micro Devices, Inc. Method for controlling transistor spacer width
HU229705B1 (en) * 2000-02-08 2014-05-28 Euro Celtique Sa Tamper-resistant oral opioid agonist formulations
WO2001092188A1 (en) 2000-05-29 2001-12-06 Shionogi & Co., Ltd. Method for labeling with tritium
US7200357B2 (en) * 2000-10-20 2007-04-03 Universal Electronics Inc. Automotive storage and playback device and method for using the same
UA81224C2 (uk) 2001-05-02 2007-12-25 Euro Celtic S A Дозована форма оксикодону та її застосування
JP4814486B2 (ja) * 2001-06-05 2011-11-16 シヴィダ・インコーポレイテッド 持続放出性鎮痛性化合物
AU2002314968B2 (en) 2001-06-08 2006-12-07 Endo Pharmaceuticals, Inc. Controlled release dosage forms using acrylic polymer, and process for making the same
SI1416842T1 (sl) 2001-07-18 2009-06-30 Euro Celtique Sa Farmacevtske kombinacije oksikodona in naloksona
EP1474198B1 (en) * 2002-01-15 2015-12-30 Novartis AG System for clearing aerosols from the effective anatomic dead space
DK1578350T3 (da) * 2002-03-26 2009-08-10 Euro Celtique Sa Sammensætninger med gel-coating med depotvirkning
WO2003092648A1 (en) 2002-04-29 2003-11-13 Alza Corporation Methods and dosage forms for controlled delivery of oxycodone
US7702280B2 (en) * 2002-05-27 2010-04-20 Ntt Docomo, Inc. Mobile communication system, transmission station, reception station, relay station, communication path deciding method, and communication path deciding program
CA2487786A1 (en) 2002-05-31 2003-12-11 Alza Corporation Dosage forms and compositions for osmotic delivery of variable dosages of oxycodone
US20040058946A1 (en) * 2002-07-05 2004-03-25 Buchwald Stephen L. Abuse-resistant prodrugs of oxycodone and other pharmaceuticals
US7399488B2 (en) * 2002-07-05 2008-07-15 Collegium Pharmaceutical, Inc. Abuse-deterrent pharmaceutical compositions of opiods and other drugs
WO2004016618A1 (en) * 2002-08-15 2004-02-26 Noramco, Inc. Oxycodone-hydrochloride polymorhs
EP1603593A4 (en) 2002-11-15 2007-08-01 Branded Products For The Futur PHARMACEUTICAL COMPOSITION
EP1575584A4 (en) * 2002-11-29 2006-02-01 Forest Laboratories METHOD FOR THE TREATMENT OF ACUTE CHARACTERIZATION BY UNIFORM FORMING WITH IBUPROFEN AND OXYCODON
FR2850576B1 (fr) * 2003-02-05 2007-03-23 Ethypharm Sa Composition comprenant un melange de principes actifs, et procede de preparation
JP2006520392A (ja) 2003-03-13 2006-09-07 コントロールド・ケミカルズ・インコーポレーテッド 薬物の乱用可能性を低下させ且つ作用持続時間を延長する化合物および方法
US6864370B1 (en) * 2003-06-05 2005-03-08 Zhaiwei Lin Process for manufacturing oxycodone
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
TW201509943A (zh) 2004-03-30 2015-03-16 Euro Celtique Sa 含有小於２５ｐｐｍ１４-羥可待因酮之羥可酮鹽酸鹽之組成物、醫藥劑型、延遲釋出口服劑型及醫藥上可以接受的包裝
US20070172958A1 (en) * 2004-03-30 2007-07-26 Euro-Celtique S.A. Methods for detecting 14-hydroxy codeinone and codeinone
US20050226929A1 (en) 2004-04-12 2005-10-13 Jianbo Xie Controlled release opioid analgesic formulation
WO2006004672A1 (en) 2004-06-25 2006-01-12 Tessera, Inc. Components with posts and pads
GB0421149D0 (en) 2004-09-23 2004-10-27 Johnson Matthey Plc Preparation of oxycodone
ME01594B (me) 2005-03-04 2014-09-20 Euro Celtique Sa Postupak smanjenja alfa, beta nezasićenih ketona u opioidnim kompozicijama
ES2357216T3 (es) 2005-06-16 2011-04-20 Mallinckrodt, Inc. Una ruta de síntesis de 14-hidroxil-opiáceos a través de 1-halo-tebaína o análogos.
CA2630703C (en) 2005-11-22 2014-05-20 Controlled Chemicals, Inc. Processes for reducing contaminating michael acceptor levels in oxycodone and other compositions
US20070117826A1 (en) 2005-11-23 2007-05-24 Forest Laboratories, Inc. Pharmaceutical formulations comprising ibuprofen, oxycodone, and 14-hydroxycodeinone
CN101395159A (zh) 2006-03-02 2009-03-25 马林克罗特公司 制备含有低含量α,β-不饱和酮化合物的吗啡烷-6-酮产物的方法
SA07280459B1 (ar) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
ES2393221T3 (es) * 2006-12-04 2012-12-19 Noramco, Inc. Procedimiento de preparación de oxicodona con niveles reducidos de 14-hidroxicodeinona
WO2008070656A2 (en) 2006-12-04 2008-06-12 Noramco, Inc Process for reducing impurities in oxycodone base
GB2450691A (en) 2007-07-02 2009-01-07 Alpharma Aps One-pot preparation of oxycodone from thebaine
PL2588481T3 (pl) * 2010-07-02 2018-05-30 Johnson Matthey Public Limited Company Sposób syntezy i oczyszczania oksykodonu
US9062062B1 (en) * 2013-12-18 2015-06-23 Cody Laboratories, Inc. Synthesis of oxycodone hydrochloride

Also Published As

Publication number Publication date
KR100930730B1 (ko) 2009-12-09
US20160175300A1 (en) 2016-06-23
CA2774121C (en) 2016-02-16
WO2005097801A1 (en) 2005-10-20
DK200700214U1 (da) 2007-11-23
US20070117829A1 (en) 2007-05-24
HUE036451T2 (hu) 2018-07-30
US11384091B2 (en) 2022-07-12
RS53891B1 (sr) 2015-08-31
CY1120171T1 (el) 2018-12-12
JP4912294B2 (ja) 2012-04-11
CN101812065A (zh) 2010-08-25
US20070179169A1 (en) 2007-08-02
PL2319846T3 (pl) 2016-12-30
KR20200000499A (ko) 2020-01-02
US9777011B2 (en) 2017-10-03
IL213890A0 (en) 2011-07-31
IL213888A0 (en) 2011-07-31
US20210198268A1 (en) 2021-07-01
SI1730151T2 (sl) 2021-03-31
NO337669B1 (no) 2016-05-30
US20150265597A1 (en) 2015-09-24
EP1730151A1 (en) 2006-12-13
CY1116327T1 (el) 2017-02-08
PT2426132E (pt) 2016-03-31
AU2005230826A1 (en) 2005-10-20
CR20110376A (es) 2011-09-19
HUE029913T2 (en) 2017-04-28
CA2913355A1 (en) 2005-10-20
EP2305683B8 (en) 2015-03-04
US20130005977A1 (en) 2013-01-03
SI2316837T1 (en) 2018-05-31
US20150258086A1 (en) 2015-09-17
CN102838607A (zh) 2012-12-26
EP2305683B2 (en) 2024-09-11
HRP20110425T4 (hr) 2020-11-27
JP2017125052A (ja) 2017-07-20
JP2012072162A (ja) 2012-04-12
US20190161492A1 (en) 2019-05-30
PT2305683E (pt) 2015-05-18
KR20100069719A (ko) 2010-06-24
IL213890A (en) 2015-10-29
KR20130020962A (ko) 2013-03-04
CA2557845A1 (en) 2005-10-20
ES2566363T3 (es) 2016-04-12
HRP20150358T1 (hr) 2015-05-08
ME03068B (me) 2019-01-20
JP2015187134A (ja) 2015-10-29
RS54941B1 (sr) 2016-11-30
US20210094963A1 (en) 2021-04-01
NO20064935L (no) 2006-12-18
US20150265598A1 (en) 2015-09-24
TWI483944B (zh) 2015-05-11
US20230365578A1 (en) 2023-11-16
IL214050A (en) 2013-09-30
CN102838607B (zh) 2016-08-03
US20200087316A1 (en) 2020-03-19
DK200700214U3 (da) 2008-02-08
CA2557845C (en) 2013-10-01
SI1730151T1 (sl) 2011-06-30
US20200062772A1 (en) 2020-02-27
JP2011157370A (ja) 2011-08-18
PL1730151T3 (pl) 2011-08-31
MY154985A (en) 2015-08-28
KR100993911B1 (ko) 2010-11-11
US20110207762A1 (en) 2011-08-25
US9522919B2 (en) 2016-12-20
HRP20110425T1 (en) 2011-07-31
CA2774121A1 (en) 2005-10-20
MY172063A (en) 2019-11-13
HUE028233T2 (en) 2016-12-28
LT2314589T (lt) 2023-06-12
RS57000B1 (sr) 2018-05-31
RS51693B (sr) 2011-10-31
CN102127086A (zh) 2011-07-20
US8822687B2 (en) 2014-09-02
KR20150046393A (ko) 2015-04-29
US20070117830A1 (en) 2007-05-24
SG10201406658VA (en) 2014-12-30
ECSP066953A (es) 2006-12-20
SG170735A1 (en) 2011-05-30
IL213889A0 (en) 2011-07-31
IL213889A (en) 2012-06-28
CN102887903B (zh) 2016-01-27
HRP20160885T1 (hr) 2016-09-23
ZA200607181B (en) 2007-11-28
DK2305683T3 (en) 2015-04-07
ES2362282T3 (es) 2011-06-30
CY1111487T1 (el) 2015-08-05
EP2316837A1 (en) 2011-05-04
EP2314589B1 (en) 2022-12-28
CY1117841T1 (el) 2017-05-17
IL178038A0 (en) 2006-12-31
CA2913355C (en) 2021-04-20
ME02411B (me) 2016-09-20
SI2305683T1 (sl) 2015-04-30
KR20070022033A (ko) 2007-02-23
RS54598B1 (sr) 2016-08-31
AR049012A1 (es) 2006-06-21
US20180022754A1 (en) 2018-01-25
AU2005230826C1 (en) 2014-10-16
SG170736A1 (en) 2011-05-30
US20070117831A1 (en) 2007-05-24
TW201231469A (en) 2012-08-01
EP2426132A1 (en) 2012-03-07
KR20090104145A (ko) 2009-10-05
AP2232A (en) 2011-05-04
CN102127086B (zh) 2013-11-27
PL2426132T3 (pl) 2016-06-30
US20160185789A1 (en) 2016-06-30
EA013208B1 (ru) 2010-04-30
DK2316837T3 (en) 2018-04-16
US20230159548A1 (en) 2023-05-25
KR101200700B1 (ko) 2012-11-13
AU2009200335B2 (en) 2011-07-28
NZ549430A (en) 2010-05-28
PE20050880A1 (es) 2005-11-16
JP5543991B2 (ja) 2014-07-09
SI2426132T1 (sl) 2016-04-29
US7674798B2 (en) 2010-03-09
EP1730151A4 (en) 2007-05-23
US10689389B2 (en) 2020-06-23
EP1730151B2 (en) 2020-09-16
PL2316837T3 (pl) 2018-07-31
CN102887903A (zh) 2013-01-23
US20160251365A1 (en) 2016-09-01
US10259819B2 (en) 2019-04-16
AU2009200335A1 (en) 2009-02-26
IL178038A (en) 2015-10-29
EP1730151B1 (en) 2011-03-09
EP2426132B1 (en) 2016-01-13
US7129248B2 (en) 2006-10-31
DK1730151T3 (da) 2011-06-20
CN101812065B (zh) 2012-03-28
JP2012188439A (ja) 2012-10-04
HRP20180407T1 (hr) 2018-04-20
PT2319846T (pt) 2016-08-12
US20160185788A1 (en) 2016-06-30
US7674800B2 (en) 2010-03-09
LT2316837T (lt) 2018-04-10
ES2535618T3 (es) 2015-05-13
RS51693B2 (sr) 2021-02-26
HK1155728A1 (en) 2012-05-25
KR101410141B1 (ko) 2014-06-25
JP2014139205A (ja) 2014-07-31
KR20120046309A (ko) 2012-05-09
TWI365880B (en) 2012-06-11
HK1155729A1 (en) 2012-05-25
DE202005021371U1 (de) 2007-10-25
NZ601326A (en) 2013-10-25
PT1730151E (pt) 2011-06-01
EP2316837B1 (en) 2018-01-10
DE602005026786D1 (de) 2011-04-21
US20160251363A1 (en) 2016-09-01
BRPI0508758B8 (pt) 2021-05-25
PT2316837T (pt) 2018-04-02
MX2020008878A (es) 2020-11-09
ES2938727T3 (es) 2023-04-14
US20050222188A1 (en) 2005-10-06
ES2585576T3 (es) 2016-10-06
EP2305683B1 (en) 2015-01-28
ES2362282T5 (es) 2021-06-24
SI2319846T1 (sl) 2016-08-31
AT9952U1 (de) 2008-06-15
ATE501150T1 (de) 2011-03-15
EP2305683A1 (en) 2011-04-06
BRPI0508758A (pt) 2007-08-28
KR20180088505A (ko) 2018-08-03
EP2319846A1 (en) 2011-05-11
IL241117B (en) 2020-06-30
US10696684B2 (en) 2020-06-30
KR20110110377A (ko) 2011-10-06
US20160176888A1 (en) 2016-06-23
CY1117228T1 (el) 2017-04-05
HK1098745A1 (en) 2007-07-27
US7674799B2 (en) 2010-03-09
FI7843U1 (fi) 2008-04-28
EP2311839A1 (en) 2011-04-20
AP2006003738A0 (en) 2006-10-31
IL214050A0 (en) 2011-08-31
CN1960994B (zh) 2012-09-05
DK2426132T3 (en) 2016-04-04
IL213891A0 (en) 2011-07-31
JP5378486B2 (ja) 2013-12-25
US20100152449A1 (en) 2010-06-17
FIU20070284U0 (fi) 2007-07-04
EP2319846B1 (en) 2016-05-04
US12060361B2 (en) 2024-08-13
MY143205A (en) 2011-03-31
IL235298A (en) 2016-11-30
CR8593A (es) 2007-07-19
US20160250204A1 (en) 2016-09-01
CN1960994A (zh) 2007-05-09
IL241117A0 (en) 2015-11-30
PL2305683T3 (pl) 2015-07-31
US7683072B2 (en) 2010-03-23
KR20120106784A (ko) 2012-09-26
US10407434B2 (en) 2019-09-10
BRPI0508758B1 (pt) 2018-10-09
EP2314589A1 (en) 2011-04-27
DK2319846T3 (en) 2016-08-15
JP5118223B2 (ja) 2013-01-16
PL1730151T5 (pl) 2023-09-18
KR20140021716A (ko) 2014-02-20
HRP20160223T1 (hr) 2016-03-25
ES2665287T3 (es) 2018-04-25
US20060173029A1 (en) 2006-08-03
MX363228B (es) 2019-03-15
JP2007531756A (ja) 2007-11-08
US20090227615A1 (en) 2009-09-10
ME02482B (me) 2017-02-20
US20160175298A1 (en) 2016-06-23
US20160175299A1 (en) 2016-06-23
DK1730151T4 (da) 2020-10-19
US20160264588A1 (en) 2016-09-15
KR20140133615A (ko) 2014-11-19
EA200601520A1 (ru) 2007-02-27
US20160251364A1 (en) 2016-09-01
NZ602862A (en) 2014-01-31
US11236098B2 (en) 2022-02-01
ME01299B (me) 2011-10-31
US9073933B2 (en) 2015-07-07
US20160185790A1 (en) 2016-06-30
US20160176889A1 (en) 2016-06-23
JP6503392B2 (ja) 2019-04-17
JP2018184462A (ja) 2018-11-22
TW200540177A (en) 2005-12-16
US20160250205A1 (en) 2016-09-01
MA28492B1 (fr) 2007-03-01
AU2005230826B2 (en) 2008-11-06

Similar Documents

Publication Publication Date Title
TWI483944B (zh) 含有小於２５ｐｐｍ１４-羥可待因酮之羥可酮鹽酸鹽組成物、醫藥劑型、延遲釋出口服劑型及醫藥上可以接受的包裝
AU2017204741B2 (en) Process for preparing oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone
MXPA06010255A (en) Process for preparing oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone
HK1149561A (en) Process for preparing oxycodone hydrochloride having less than 25ppm 14-hydroxycodeinone